GSK
Promega to Develop Microsatellite Instability Companion Diagnostic Kit With GlaxoSmithKline
The IVD kit will be used to identify patients with the MSI biomarker who may be eligible for potential treatment with GSK's Jemperli (dostarlimab-gxly).
Precision Cancer Consortium Launches With Bayer, GSK, Roche, Novartis as Founding Members
The organization of pharmaceutical and biotechnology firms aims to increase access to genomic testing for cancer patients.
FDA Approves GlaxoSmithKline's Jemperli, Roche’s Ventana CDx for dMMR Solid Cancers
The approval expands the label for GSK's anti-PD-1 agent dostarlimab, which the FDA initially approved in April for patients with dMMR endometrial cancers.
FDA Approves GSK's Jemperli With Ventana CDx for dMMR Endometrial Cancer
The FDA also approved the Ventana MMR RxDx panel as a companion diagnostic to select endometrial cancer patients for treatment with dostarlimab.
COVID-19 Pandemic Accelerated Development of CRISPR as a Diagnostic Platform in 2020
The pace of development for CRISPR-based infectious disease assays increased as the pandemic progress